HeartSciences Secures European Patent for AI-ECG Diastolic Function Assessment, Expanding IP Portfolio
HSCS is trading near its 52-week low of $1.63 (13% above the low).
Summary
HeartSciences has been granted a European patent for its ECG-based assessment of diastolic function, expanding its intellectual property portfolio to over 45 patents. This patent covers machine-learning models that use ECG data to estimate echocardiogram parameters. The new IP strengthens the company's core AI-ECG technology, which aims to transform ECG into a more valuable cardiac screening tool, particularly in the European market. This positive product development follows recent commercial agreements for its MyoVista Insights platform, but also comes amidst the company's ongoing financial challenges, including recent 'going concern' warnings and significant share dilution.
At the time of this announcement, HSCS was trading at $1.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6M. The 52-week trading range was $1.63 to $6.47. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.